Droplet Biosciences

Droplet Biosciences is an early-stage diagnostics company developing a proprietary platform to analyze post-surgical lymphatic fluid, a previously inaccessible biofluid, for the detection of minimal residual disease. The company's lead product, LymphDetect™ Head & Neck, is a CLIA test that detects ctDNA in drain fluid from head and neck cancer surgeries, aiming to provide superior sensitivity and earlier recurrence risk assessment than blood-based tests. By leveraging the lymphatic system's proximity to the tumor site, Droplet seeks to enable more timely and precise adjuvant treatment decisions, potentially improving patient outcomes. The company is collaborating with leading medical centers and has announced a technology partnership with NVIDIA to accelerate its bioinformatics pipeline.

Proprietary 'lymph liquid biopsy' platform that harvests and analyzes post-surgical lymphatic drain fluid using next-generation sequencing (NGS) and accelerated bioinformatics (via NVIDIA Parabricks) to detect circulating tumor DNA (ctDNA) for minimal residual disease assessment.

Droplet competes primarily with companies offering blood-based ctDNA tests for MRD detection (e.g., Natera's Signatera, Guardant Health's Guardant Reveal). Its key differentiation is the use of proximal lymph fluid, which it claims offers superior sensitivity for locoregional recurrence earlier than blood tests. It also faces competition from traditional pathology and imaging for recurrence monitoring.